This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang, S. L.
Right arrow Articles by Rybak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, S. L.
Right arrow Articles by Rybak, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 07 1995, 1505-1511, Vol 39, No. 7
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model

SL Kang and MJ Rybak
Department of Pharmacy Services, Detroit Receiving Hospital, University Health Center, Michigan, USA.

The bactericidal activity and emergence of resistance to RP 59500 (quinupristin/dalfopristin) when it was administered alone and in combination with vancomycin against fibrin clots that have been infected with methicillin-susceptible Staphylococcus aureus ATCC 25923 or methicillin-resistant S. aureus (MRSA) 67 were evaluated in an in vitro pharmacodynamic infected fibrin clot model. Fibrin clots were infected with S. aureus to achieve an inoculum of approximately 10(9) CFU/g. Antibiotics were administered to simulate pharmacokinetics in humans: RP 59500 (7.5 mg/kg of body weight) every 8 h and vancomycin (15 mg/kg) every 12 h over 72 h. Preliminary test tube time-kill experiments with an inoculum of approximately 10(5) CFU/ml suggested that RP 59500 was more rapid in achieving a 99.9% reduction in the number of CFU per milliliter than vancomycin against ATCC 25923 (6.94 versus 24 h; P = 0.0003) and MRSA 67 (6.77 versus 17.03 h; P = 0.004). At a higher inoculum (approximately 10(8) CFU/ml), 99.9% kill was achieved only with the combination regimen against ATCC 25923 and MRSA 67 (10.9 and 10.5 h, respectively), with total reductions of 6.35 and 6.33 log10 CFU/ml over 24 h, respectively. In the fibrin clot model, RP 59500 was more effective than vancomycin in reducing organism titers over 72 h.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:

  • Nguyen, H. M., Graber, C. J. (2009). Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?. J Antimicrob Chemother 0: dkp377v1-dkp377 [Abstract] [Full Text]  
  • Mercier, R.-C., Dietz, R. M., Mazzola, J. L., Bayer, A. S., Yeaman, M. R. (2004). Beneficial Influence of Platelets on Antibiotic Efficacy in an In Vitro Model of Staphylococcus aureus-Induced Endocarditis. Antimicrob. Agents Chemother. 48: 2551-2557 [Abstract] [Full Text]  
  • Lee, D.-G., Chun, H.-S., Yim, D.-S., Choi, S.-M., Choi, J.-H., Yoo, J.-H., Shin, W.-S., Kang, M.-W. (2003). Efficacies of Vancomycin, Arbekacin, and Gentamicin Alone or in Combination against Methicillin-Resistant Staphylococcus aureus in an In Vitro Infective Endocarditis Model. Antimicrob. Agents Chemother. 47: 3768-3773 [Abstract] [Full Text]  
  • Pavie, J., Lefort, A., Zarrouk, V., Chau, F., Garry, L., Leclercq, R., Fantin, B. (2002). Efficacies of Quinupristin-Dalfopristin Combined with Vancomycin In Vitro and in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus in Relation to Cross-Resistance to Macrolides, Lincosamides, and Streptogramin B- Type Antibiotics. Antimicrob. Agents Chemother. 46: 3061-3064 [Abstract] [Full Text]  
  • Allen, G. P., Cha, R., Rybak, M. J. (2002). In Vitro Activities of Quinupristin-Dalfopristin and Cefepime, Alone and in Combination with Various Antimicrobials, against Multidrug-Resistant Staphylococci and Enterococci in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 46: 2606-2612 [Abstract] [Full Text]  
  • Malbruny, B., Canu, A., Bozdogan, B., Fantin, B., Zarrouk, V., Dutka-Malen, S., Feger, C., Leclercq, R. (2002). Resistance to Quinupristin-Dalfopristin Due to Mutation of L22 Ribosomal Protein in Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 2200-2207 [Abstract] [Full Text]  
  • Putman, M., van Veen, H. W., Degener, J. E., Konings, W. N. (2001). The lactococcal secondary multidrug transporter LmrP confers resistance to lincosamides, macrolides, streptogramins and tetracyclines. Microbiology 147: 2873-2880 [Abstract] [Full Text]  
  • Cetinkaya, Y., Falk, P., Mayhall, C. G. (2000). Vancomycin-Resistant Enterococci. Clin. Microbiol. Rev. 13: 686-707 [Abstract] [Full Text]  
  • Mercier, R.-C., Rybak, M. J., Bayer, A. S., Yeaman, M. R. (2000). Influence of Platelets and Platelet Microbicidal Protein Susceptibility on the Fate of Staphylococcus aureus in an In Vitro Model of Infective Endocarditis. Infect. Immun. 68: 4699-4705 [Abstract] [Full Text]  
  • Houlihan, H. H., Stokes, D. P., Rybak, M. J. (2000). Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model. J Antimicrob Chemother 46: 79-86 [Abstract] [Full Text]  
  • Aeschlimann, J. R., Zervos, M. J., Rybak, M. J. (1998). Treatment of Vancomycin-Resistant Enterococcus faecium with RP 59500 (Quinupristin-Dalfopristin) Administered by Intermittent or Continuous Infusion, Alone or in Combination with Doxycycline, in an In Vitro Pharmacodynamic Infection Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 42: 2710-2717 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»